Cargando…

Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma

Dickkopf-1 (DKK-1) and sclerostin are essential Wnt/β-catenin pathway inhibitors, playing an important role in multiple myeloma bone disease (MBD). We aimed to examine the serum DKK-1 and sclerostin variations in newly diagnosed multiple myeloma (NDMM) patients at diagnosis and in the course of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerov, Vladimir, Gerova, Daniela, Micheva, Ilina, Nikolova, Miglena, Mihaylova, Galya, Galunska, Bistra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342782/
https://www.ncbi.nlm.nih.gov/pubmed/37445475
http://dx.doi.org/10.3390/jcm12134440
_version_ 1785072581653561344
author Gerov, Vladimir
Gerova, Daniela
Micheva, Ilina
Nikolova, Miglena
Mihaylova, Galya
Galunska, Bistra
author_facet Gerov, Vladimir
Gerova, Daniela
Micheva, Ilina
Nikolova, Miglena
Mihaylova, Galya
Galunska, Bistra
author_sort Gerov, Vladimir
collection PubMed
description Dickkopf-1 (DKK-1) and sclerostin are essential Wnt/β-catenin pathway inhibitors, playing an important role in multiple myeloma bone disease (MBD). We aimed to examine the serum DKK-1 and sclerostin variations in newly diagnosed multiple myeloma (NDMM) patients at diagnosis and in the course of therapy, including autologous stem cell transplantation (ASCT). This study included 41 NDMM-patients and 33 controls. MBD was assessed by whole-body low-dose computed tomography. DKK-1 and sclerostin were assayed by commercial ELISA kits. At diagnosis, NDMM-patients revealed significantly higher DKK-1 and sclerostin values (p < 0.0001), showing dependence on disease stage (lowest in ISS-I and highest in ISS-III: p < 0.0012 and p < 0.025, respectively, for both proteins). Bone lesions revealed significant positive correlation with both DKK-1 (p < 0.05) and sclerostin (p < 0.0001). In the course of therapy, significant reduction, more prominent after ASCT, was observed for both parameters in each treatment point compared to the baseline (p < 0.0001). Markedly lower sclerostin (p < 0.01) and DKK-1 (p < 0.05) values were observed in patients with complete and very good partial response compared to those with partial response, stable, or progressive disease. Sclerostin and DKK-1 in NDMM patients reflect the MBD severity and the effect of therapy. Both proteins could represent a novel tool for better disease monitoring and effectiveness of therapy.
format Online
Article
Text
id pubmed-10342782
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103427822023-07-14 Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma Gerov, Vladimir Gerova, Daniela Micheva, Ilina Nikolova, Miglena Mihaylova, Galya Galunska, Bistra J Clin Med Article Dickkopf-1 (DKK-1) and sclerostin are essential Wnt/β-catenin pathway inhibitors, playing an important role in multiple myeloma bone disease (MBD). We aimed to examine the serum DKK-1 and sclerostin variations in newly diagnosed multiple myeloma (NDMM) patients at diagnosis and in the course of therapy, including autologous stem cell transplantation (ASCT). This study included 41 NDMM-patients and 33 controls. MBD was assessed by whole-body low-dose computed tomography. DKK-1 and sclerostin were assayed by commercial ELISA kits. At diagnosis, NDMM-patients revealed significantly higher DKK-1 and sclerostin values (p < 0.0001), showing dependence on disease stage (lowest in ISS-I and highest in ISS-III: p < 0.0012 and p < 0.025, respectively, for both proteins). Bone lesions revealed significant positive correlation with both DKK-1 (p < 0.05) and sclerostin (p < 0.0001). In the course of therapy, significant reduction, more prominent after ASCT, was observed for both parameters in each treatment point compared to the baseline (p < 0.0001). Markedly lower sclerostin (p < 0.01) and DKK-1 (p < 0.05) values were observed in patients with complete and very good partial response compared to those with partial response, stable, or progressive disease. Sclerostin and DKK-1 in NDMM patients reflect the MBD severity and the effect of therapy. Both proteins could represent a novel tool for better disease monitoring and effectiveness of therapy. MDPI 2023-07-01 /pmc/articles/PMC10342782/ /pubmed/37445475 http://dx.doi.org/10.3390/jcm12134440 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gerov, Vladimir
Gerova, Daniela
Micheva, Ilina
Nikolova, Miglena
Mihaylova, Galya
Galunska, Bistra
Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
title Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
title_full Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
title_fullStr Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
title_full_unstemmed Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
title_short Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
title_sort dynamics of bone disease biomarkers dickkopf-1 and sclerostin in patients with multiple myeloma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342782/
https://www.ncbi.nlm.nih.gov/pubmed/37445475
http://dx.doi.org/10.3390/jcm12134440
work_keys_str_mv AT gerovvladimir dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma
AT gerovadaniela dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma
AT michevailina dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma
AT nikolovamiglena dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma
AT mihaylovagalya dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma
AT galunskabistra dynamicsofbonediseasebiomarkersdickkopf1andsclerostininpatientswithmultiplemyeloma